
Drug maker GSK has secured a payment of up to 500 million dollars (£372 million) after a patent row over Covid vaccines was settled in the US.
GSK told investors it will receive a 370 million dollar (£275 million) settlement from CureVac, which it had worked with on the development of mRNA vaccine technology.